Abstract
The current review will focus on the recent patents for AMPA receptor antagonists and their claims, evidence for their therapeutic effectiveness in the treatment of epilepsy and their potential role in psychiatric and neurodegenerative disorders. It will also highlight the proposed mechanisms of action and the implications thereof for our current understanding of the biomolecular basis of these pathologies. It will conclude with a summary of what we know, but also point out the remaining uncertainties, especially as this relates to the claims in the patent under discussion.
Keywords: AMPA, glutamate, antagonist, epilepsy, schizophrenia, ALS, multiple sclerosis, neuroprotection, anxiety, antiproliferative
Recent Patents on CNS Drug Discovery (Discontinued)
Title: AMPA Receptor Antagonists: Potential Therapeutic Applications
Volume: 1 Issue: 3
Author(s): Henri Mattes, Kurt Lingenhoehl, Hans Kalkman, Yves Auberson, Johanne Renaud, Markus Schmutz and David Orain
Affiliation:
Keywords: AMPA, glutamate, antagonist, epilepsy, schizophrenia, ALS, multiple sclerosis, neuroprotection, anxiety, antiproliferative
Abstract: The current review will focus on the recent patents for AMPA receptor antagonists and their claims, evidence for their therapeutic effectiveness in the treatment of epilepsy and their potential role in psychiatric and neurodegenerative disorders. It will also highlight the proposed mechanisms of action and the implications thereof for our current understanding of the biomolecular basis of these pathologies. It will conclude with a summary of what we know, but also point out the remaining uncertainties, especially as this relates to the claims in the patent under discussion.
Export Options
About this article
Cite this article as:
Mattes Henri, Lingenhoehl Kurt, Kalkman Hans, Auberson Yves, Renaud Johanne, Schmutz Markus and Orain David, AMPA Receptor Antagonists: Potential Therapeutic Applications, Recent Patents on CNS Drug Discovery (Discontinued) 2006; 1 (3) . https://dx.doi.org/10.2174/157488906778773698
DOI https://dx.doi.org/10.2174/157488906778773698 |
Print ISSN 1574-8898 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3954 |
Related Articles
-
Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?
CNS & Neurological Disorders - Drug Targets Sleep Disorders Research From 1945 to 2020: A Bibliometric Analysis
CNS & Neurological Disorders - Drug Targets Transglutaminases as Possible Therapeutic Targets in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Carbon-11 Labeled Tracers for In Vivo Imaging of P-Glycoprotein Function: Kinetics, Advantages and Disadvantages
Current Topics in Medicinal Chemistry Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Current Neuropharmacology Clinical Pharmacokinetics of Retigabine/Ezogabine
Current Clinical Pharmacology Optimized Feature Selection for Enhanced Epileptic Seizure Detection
Current Medical Imaging Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Cell Type Specificity of GABAA Receptor Mediated Signaling in the Hippocampus
Current Drug Targets - CNS & Neurological Disorders D-Serine Regulation: A Possible Therapeutic Approach for Central Nervous Diseases and Chronic Pain
Mini-Reviews in Medicinal Chemistry Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?
Current Neuropharmacology Altered Homeostatic Functions in Reactive Astrocytes and Their Potential as a Therapeutic Target After Brain Ischemic Injury
Current Pharmaceutical Design Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Voltage Gated ion Channels: Targets for Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Small Molecule Modulation of p75 Neurotrophin Receptor Functions
CNS & Neurological Disorders - Drug Targets Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry